Genetic PML Risk Screening for Safer Immunosuppressive Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately predict who is at risk of developing progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal opportunistic infection, due to the insufficient predictive power of known risk factors, necessitating a companion diagnostic test to identify individuals at low risk for PML to ensure safe administration of immunosuppressive therapies.
Innovation Solution
Administering a therapeutically effective amount of immunosuppressive medications to subjects identified as low risk for PML through genetic testing, which detects the absence of specific genetic variations occurring at low frequencies in PML populations, thereby reducing the risk of PML infection by John Cunningham virus (JCV).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If known risk factors are used to predict PML risk, then some risk identification is achieved, but the predictive accuracy is insufficient
Solution Approach 1:
The patent segments the risk prediction process into multiple independent genetic markers (CSF1, ITGAM, ITGAX, LILRB2, LILRB4, CD47) that can be evaluated separately and combined. Each marker is tested individually for its association with PML risk, and the results are integrated to provide a comprehensive risk assessment, thereby improving predictive accuracy beyond single-factor evaluation
Solution Approach 2:
The patent changes the parameter being measured from general immune status to specific genetic variations in immune-related genes. By identifying particular polymorphisms and mutations in these genes, the test transforms the prediction approach from observing clinical risk factors to measuring genetic susceptibility parameters, significantly enhancing predictive precision
2Reliability
If immunosuppressive therapy is administered to high-risk individuals, then treatment efficacy is achieved, but PML occurrence increases
Solution Approach 1:
The patent performs preliminary genetic testing before initiating immunosuppressive therapy to identify individuals at low risk for PML. By assessing genetic markers in advance, the system enables pre-screening of patients, allowing clinicians to proceed with treatment only after confirming low genetic susceptibility, thereby preventing PML before it occurs
Solution Approach 2:
The patent applies preliminary anti-action by identifying and excluding high-risk individuals before exposure to immunosuppressive agents. The genetic test detects susceptibility markers that would predispose patients to PML, allowing the harmful effect (PML infection) to be prevented in advance by avoiding the triggering intervention (immunosuppressive therapy) in susceptible individuals
3Reliability
If genetic testing is implemented to identify low-risk subjects, then treatment safety improves, but diagnostic complexity increases
Solution Approach 1:
The patent creates a universal diagnostic platform that can simultaneously evaluate multiple genetic markers (CSF1, ITGAM, ITGAX, LILRB2, LILRB4, CD47) using a single integrated test system. This multi-functional approach consolidates what would otherwise require multiple separate assays into one comprehensive genetic panel, maintaining high reliability while managing diagnostic complexity through standardization
Data Source
AI summary
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.